Home
Live Updates
Pathios Therapeutics Unveils PTT-4256, a Highly Potent and Selective Inhibitor of GPR65, in Presentation at American Association for Cancer Research (AACR) Annual Meeting 2023 : comparemela.com
Pathios Therapeutics Unveils PTT-4256, a Highly Potent and Selective Inhibitor of GPR65, in Presentation at American Association for Cancer Research (AACR) Annual Meeting 2023
/PRNewswire/ -- Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced...
Related Keywords
United States ,
United Kingdom ,
Florida ,
Orlando ,
American ,
Stuart Hughes ,
Tim Brons ,
American Association For Cancer Research ,
Innovation Centre On Milton Park ,
Prnewswire Pathios Therapeutics Limited ,
Discovery Program Counteracts Immunosuppressive Polarization Of Macrophages ,
Latest Small Molecule ,
Macrophages Triggered ,
Acidic Tumor Microenvironment ,
Impressive Anti Tumor Activity ,
Preclinical Cancer Models Following Oral Dosing ,
Therapeutics Limited ,
American Association ,
Cancer Research ,
Annual Meeting ,
Canaan Partners ,
Innovation Centre ,
Milton Park ,
Chief Executive ,
Strategic Partners ,
Pathios Therapeutics ,
comparemela.com © 2020. All Rights Reserved.